Some of the drugs that have been used clinically to treat type 2 diabetes, such as tolbutamide and glibenclamide, also exhibit cross-inhibition of SUR2-containing KATP channels [14]. The gene discussed is ABCC9; the disease is type 2 diabetes mellitus.